{"title":"Quality of life after treatment of vestibular schwannomas.","authors":"Morten Lund-Johansen","doi":"10.1016/B978-0-12-824534-7.00022-6","DOIUrl":null,"url":null,"abstract":"<p><p>Over the last two decades, health-related quality of life (QOL) in vestibular schwannoma patients has gained increasing attention among caretakers, and patient-reported outcomes are frequently included in clinical studies, as a secondary or even primary outcome. Numerous general and disease-specific questionnaires exist, as well as questionnaires directed toward specific symptoms, such as hearing loss or vestibular complaints. When evaluating score outcomes, a small, statistically significant difference may not be clinically relevant. For several scoring systems such as the PANQOL questionnaire, the minimal clinically identifiable difference (MCID) has been identified and should be used when analyzing data. The main generator of generally reduced QOL in VS patients is vestibular complaints, in particular dizziness. When comparing groups receiving observation, or radiosurgery or surgery, differences in response tend to be minor, both between groups as well as before and after treatment. In most studies, patients operated tend to report somewhat lower than others, but the differences are quite small. In one study including non-VS responders, there were, however, highly significant differences in score outcomes between patients and controls; thus, it seems that being a VS patient is the main driver of outcome and that treatment modality has a lower impact. Future research on QOL in VS patients should direct toward a refinement of instruments, and toward prospectively designed studies with baseline and follow-up recordings.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"212 ","pages":"341-346"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Handbook of clinical neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/B978-0-12-824534-7.00022-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Over the last two decades, health-related quality of life (QOL) in vestibular schwannoma patients has gained increasing attention among caretakers, and patient-reported outcomes are frequently included in clinical studies, as a secondary or even primary outcome. Numerous general and disease-specific questionnaires exist, as well as questionnaires directed toward specific symptoms, such as hearing loss or vestibular complaints. When evaluating score outcomes, a small, statistically significant difference may not be clinically relevant. For several scoring systems such as the PANQOL questionnaire, the minimal clinically identifiable difference (MCID) has been identified and should be used when analyzing data. The main generator of generally reduced QOL in VS patients is vestibular complaints, in particular dizziness. When comparing groups receiving observation, or radiosurgery or surgery, differences in response tend to be minor, both between groups as well as before and after treatment. In most studies, patients operated tend to report somewhat lower than others, but the differences are quite small. In one study including non-VS responders, there were, however, highly significant differences in score outcomes between patients and controls; thus, it seems that being a VS patient is the main driver of outcome and that treatment modality has a lower impact. Future research on QOL in VS patients should direct toward a refinement of instruments, and toward prospectively designed studies with baseline and follow-up recordings.
期刊介绍:
The Handbook of Clinical Neurology (HCN) was originally conceived and edited by Pierre Vinken and George Bruyn as a prestigious, multivolume reference work that would cover all the disorders encountered by clinicians and researchers engaged in neurology and allied fields. The first series of the Handbook (Volumes 1-44) was published between 1968 and 1982 and was followed by a second series (Volumes 45-78), guided by the same editors, which concluded in 2002. By that time, the Handbook had come to represent one of the largest scientific works ever published. In 2002, Professors Michael J. Aminoff, François Boller, and Dick F. Swaab took on the responsibility of supervising the third (current) series, the first volumes of which published in 2003. They have designed this series to encompass both clinical neurology and also the basic and clinical neurosciences that are its underpinning. Given the enormity and complexity of the accumulating literature, it is almost impossible to keep abreast of developments in the field, thus providing the raison d''être for the series. The series will thus appeal to clinicians and investigators alike, providing to each an added dimension. Now, more than 140 volumes after it began, the Handbook of Clinical Neurology series has an unparalleled reputation for providing the latest information on fundamental research on the operation of the nervous system in health and disease, comprehensive clinical information on neurological and related disorders, and up-to-date treatment protocols.